Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting
The conference disclosures offer an early view of late‑stage results alongside long‑term follow‑up for a new KV7 therapy.
Overview
- Xenon Pharmaceuticals presented Phase 3 X‑TOLE2 results for azetukalner in adults with focal onset seizures at the American Academy of Neurology meeting in a late‑breaking session.
- Focal onset seizures begin in one area of the brain, and azetukalner is described as a KV7 channel opener being developed for this form of epilepsy.
- An ongoing seven‑year open‑label extension reported an interim analysis at or beyond 48 months of treatment for adults with focal epilepsy.
- A separate poster shared real‑world views on anti‑seizure medication titration, covering dose changes, treatment burden, quality of life, and interest in no‑titration options.
- Xenon disclosed the presentation lineup in a company press release distributed by Benzinga, which also listed investor and media contacts.